Mallia Therapeutics GmbH |

Mallia Therapeutics GmbH

Mallia Therapeutics GmbH is a biopharmaceutical company focused on developing novel treatments for patients suffering from hair loss. Hormone-induced male or female pattern hair loss (androgenetic alopecia) affects over half of all men and many women. Mallia Therapeutics aims to enter the multi-billion-dollar alopecia market by offering patients a safe and effective topical therapy based on the human soluble protein sCD83. Promising preclinical data show that the immunomodulator sCD83 stimulates both hair growth and new hair follicle formation via a dual mechanism of action with no evidence of the side effects common for systemic treatments. Thus, sCD83 should offer distinct advantages over marketed treatments. The Company is led by an experienced management team and worldwide leading experts in the field of CD83 biology.

About Mallia Therapeutics GmbH:

Field of Activity	Mallia Therapeutics develops sCD83 for the treatment of hormone-induced male or female pattern baldness (= androgenetic alopecia) and autoimmune mediated male or female patchy hair loss (= alopecia areata), the two most prevalent forms of hair loss.
Ownership Structure and Financing	Private company; seed funding secured, and Series A planned to finance clinical development
Technology	sCD83 is a human derived protein that induces new hair growth when applied topically. In preclinical in vivo models, it induces an anti-inflammatory milieu and thereby promotes hair growth. In addition, sCD83 directly binds to human hair follicles to activate hair follicle stem cells and thus inducing new hair growth.
USP	sCD83 can be applied topically to activate the hair follicle, which is a big advantage compared to systemic treatment options. Unlike other topical treatments, it not only accelerates hair growth, but also induces the formation of new hair follicles.

Contact:

From left to right: Dr. Dmytro Royzman, co-founder and CSO Prof. Dr. Alexander Steinkasserer, co-founder and managing director Dr. Manfred Groeppel, co-founder and managing director

Address	Mallia Therapeutics GmbH Henkestr. 91 91052 Erlangen, Germany
E-mail	info@mallia-therapeutics.com
Web Address	https://mallia-therapeutics.com/
Social Media	LinkedIn
Date of Incorporation/Number of Employees	2023/3

ARTIKEL ZU DIESEN SCHLAGWORTEN